Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,893 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Patients Clear all

Conditions: Bone Metastases, Castration-Resistant Prostate Cancer
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more

Conditions: Prostate Cancer
Interventions: capivasertib, docetaxel, placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 37
States / cities: Yuma, Arizona • Beverly Hills, California • Cerritos, California + 31 more

Conditions: Neoplasms
Interventions: PET tracer (BAY94-9392); Drug
Lead sponsor: Lantheus Biosciences Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions: Minnelide™Capsules; Drug
Lead sponsor: Minneamrita Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more

Conditions: Prostate Cancer
Interventions: goserelin acetate, leuprolide acetate, image-guided radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Prostate Cancer
Interventions: Velcade, LH-RH Agonist, Androgen Receptor Antagonists; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 4
States / cities: Loma Linda, California • Charleston, South Carolina • Columbia, South Carolina + 1 more

Conditions: Metastatic Prostate Cancer
Interventions: Provider-level and patient education at end of study, Provider-level and patient-level; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Esophageal Cancer
Interventions: PET imaging with CuATSM, PET imaging, PET CuATSM; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: enzalutamide, abiraterone acetate, prednisone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Focal prostate brachytherapy with Cesium-131; Radiation
Lead sponsor: Ronald M. Benoit, MD; Other
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 276
States / cities: Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more

Conditions: Prostate Cancer
Interventions: GM-CSF gene transduced allogeneic vaccine GVAX; Biological
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: vudalimab; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Prescott, Arizona • La Jolla, California • Los Angeles, California + 12 more

Conditions: Prostate Cancer
Interventions: patient decision aid (print-based); Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 543 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer
Interventions: Educational intervention.; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Prostate Carcinoma
Interventions: Best Practice, Computed Tomography, Electronic Health Record Review, Imaging Procedure, Questionnaire Administration, Radiation Therapy; Other · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Conditions: Hormone-Refractory Prostate Cancer
Interventions: Zoledronic Acid 20mg Tablets, Zoledronic Acid; Drug
Lead sponsor: Merrion Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Birmingham, Alabama • Lake City, Florida • Lakeland, Florida + 5 more

Conditions: Cancer Survivor, Prostate Carcinoma
Interventions: Educational Intervention, Laboratory Biomarker Analysis, Long-term Follow-up, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Male only
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: sipuleucel-T, DNA Vaccine; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Renal Cell Cancer, Prostate Cancer, Effects of Chemotherapy
Interventions: CORA- Device:smartphones"; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: [89Zr]Df-IAB2M; Radiation
Lead sponsor: ImaginAb, Inc.; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3
Interventions: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging); Drug
Lead sponsor: Aktis Oncology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Irvine, California • Miami, Florida • Kansas City, Kansas + 5 more

Conditions: Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms
Interventions: NUV-422, Enzalutamide; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Canton, Ohio • Gettysburg, Pennsylvania • Fairfax, Virginia

Conditions: Prostate Cancer
Interventions: Radiation Therapy; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Arlington, Virginia

Search by objective public record fields.

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Physician- and Patient-based Barriers to NGS Testing

Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Prostate Cancer Screening: Fostering Informed Decisions

Improving Germline Testing in At-Risk Patients With Prostate Cancer

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Long-Term Follow-Up in Patients With Prostate Cancer After Surgery

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention

A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Metabolomic Study for Localized Prostate Cancer